Voranigo® Earns Multiple Prestigious Awards
Voranigo® has recently achieved significant recognition, receiving the Prix Galien USA, Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. This string of awards highlights the remarkable advancements that Voranigo® brings to patients affected by glioma.
A Celebration of Scientific Innovation
In an exciting announcement from Servier, an independent international pharmaceutical group, Voranigo® (vorasidenib) was awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases during a prestigious ceremony held in Stockholm. These awards underscore the growing synergy between life sciences and biopharmaceutical innovations across various regions.
Recognition Across Borders
Voranigo® has not only triumphed in Sweden but also captured the attention of experts and industry leaders globally, having won the Prix Galien USA Award. These accolades exemplify the commitment to addressing the unique needs of patients living with rare diseases, particularly glioma. By bridging the gap between innovation and patient care, Voranigo® sets a new standard in the treatment landscape.
A Commitment to Patient-Centric Innovations
Arnaud Lallouette, Executive Vice-President of Global Medical & Patient Affairs, stated, "We are truly honored to receive these prestigious distinctions in several countries. It recognizes the scientific progress that Voranigo® can bring to patients living with glioma across the world. It rewards Servier's commitment to innovation and to patients as we continue to advance precision oncology for all who stand to benefit." This statement reflects Servier’s dedication not only to developing groundbreaking treatments but also to enhancing the quality of life for patients.
Marketing Authorization Details
Voranigo® has received marketing authorization for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma in adults and adolescents aged 12 years and older. This innovative treatment is specifically indicated for those who have undergone surgical intervention and are not in immediate need of radiotherapy or chemotherapy.
A Positive Impact on Glioma Patients
With marketing authorizations across various countries, including the United States, Canada, Australia, and numerous European nations, Voranigo® is positioned to make a significant impact on patients living with glioma. The recognition garnered by this product indicates a promising shift in therapeutic approaches for patients suffering from these challenging conditions.
Frequently Asked Questions
What is Voranigo®?
Voranigo® (vorasidenib) is a treatment for patients with glioma, specifically for non-enhancing Grade 2 astrocytoma or oligodendroglioma.
What awards has Voranigo® received?
Voranigo® has received the Prix Galien USA, Prix Galien Poland, and Prix Galien Bridges Awards for its innovation in treating orphan/rare diseases.
What does the Prix Galien award signify?
The Prix Galien award recognizes outstanding life science innovations that significantly advance medical treatment and patient care.
Who is Servier?
Servier is an independent international pharmaceutical company focused on research and development in various therapeutic areas, including oncology.
How does Voranigo® benefit glioma patients?
Voranigo® offers a treatment option for patients living with glioma, helping to improve their health outcomes and quality of life.
